Pharma donations to patient groups in Canada are shrouded in mystery

Donation data reported on websites by drug makers and patient advocacy groups in Canada that receive industry funding is “haphazard, inconsistent and incomplete.”

D onation data reported on websites by drug makers and patient advocacy groups in Canada that receive industry funding is “haphazard, inconsistent and incomplete,” underscoring the difficulties in deciphering the influence these companies may have on patient interests, a new analysis finds. Specifically, information about the value of donations made by drug companies, the years in which contributions were given, and the percent of income the money represented for patient groups was limited. Consequently, donations made and received often could not be matched, according to the analysis in the I

related reading

• Pharma Virumque | Slate Star Codexslatestarcodex.com
• The pharma industry from Paul Janssen to today: why drugs got harder to develop and what we can do about it | Alex’s blogatelfo.github.io
• What a time to be an oncologist - by Olivia Webb Kosloffacutecondition.com
• Top Postsslatestarcodex.com
• Canada’s laws on pharmaceutical intellectual property: the case for fundamental reformncbi.nlm.nih.gov
• Sunshine UKwhopaysthisdoctor.org
• The 23andMe Deal - Cremieux Recueilcremieux.xyz
• Cause Reportscausereports.com
• Why are our medicines so expensive? Spoiler: Not for the reasons you are being told… - PMCncbi.nlm.nih.gov
• The Competitive Advantage of Corporate Philanthropyhbr.org
• Some questions about biotech that I find interesting | Alex’s blogatelfo.github.io
• We wish we’d written that: STAT staffers' favorite stories of 2022statnews.com